These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 24105486)

  • 1. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
    Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
    Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae.
    Sun S; Li W; Sun Y; Pan Y; Li J
    Biochem Biophys Res Commun; 2011 Apr; 407(1):124-8. PubMed ID: 21362402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production in Saccharomycescerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs.
    Legendre D; Fastrez J
    J Biotechnol; 2005 May; 117(2):183-94. PubMed ID: 15823407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection.
    Dong Y; Ma T; Zhang X; Ying Q; Han M; Zhang M; Yang R; Li Y; Wang F; Liu R; Wu X
    J Med Microbiol; 2019 Mar; 68(3):480-492. PubMed ID: 30657443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
    Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ
    J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice.
    Shu C; Sun P; Xie H; Huang W; Qi J; Ma Y
    Int J Nanomedicine; 2020; 15():1983-1996. PubMed ID: 32308382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical safety of a viral vector based prostate cancer vaccine strategy.
    Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
    J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
    Simons JW; Sacks N
    Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising MS2 mediated virus-like particle vaccine against foot-and-mouth disease.
    Dong YM; Zhang GG; Huang XJ; Chen L; Chen HT
    Antiviral Res; 2015 May; 117():39-43. PubMed ID: 25676866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.